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Abstract
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Recurrence of idiopathic focal segmental glomerulosclerosis (FSGS) after renal transplantation is
believed to be caused by a circulating factor(s). We detected cardiotrophin-like cytokine 1
(CLCF1), a member of the IL-6 family, in the plasma from patients with recurrent FSGS. We
hypothesized that CLCF1 contributes to the effect of FSGS serum on the glomerular filtration
barrier in vitro. Presently, we studied the effect of CLCF1 on isolated rat glomeruli using an in
vitro assay of albumin permeability (Palb). CLCF1 (0.05–100 ng/mL) increased Palb and caused
maximal effect at 5–10 ng/mL (P<0.001). The increase in Palb was analogous to the effect of
FSGS serum. Anti-CLCF1 monoclonal antibody blocked the CLCF1-induced increase in Palb and
significantly attenuated the effect of FSGS serum (P<0.001). The heterodimer composed of
CLCF1 and co-secreted molecule cytokine receptor-like factor-1 (CRLF1) attenuated the increase
in Palb caused by CLCF1 or FSGS serum. Western blot analysis showed that CLCF1 upregulated
phosphorylation of STAT3 (Tyr705) in glomeruli. This effect was diminished by the heterodimer
CLCF1-CRLF1. JAK2 inhibitor BMS-1119543 or STAT3 inhibitor Stattic significantly blocked
the effect of CLCF1 or FSGS serum on Palb (P<0.001). These novel findings suggest that while

Author Manuscript

Correspondence, Mukut Sharma, F2-120, Research Service, Building 15, 4801 E Linwood Blvd, STOP 151, Kansas City VA Medical
Center, Kansas City, MO, Telephone: 816-861-4700 extn 56626 Mukut.sharma@va.gov.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Parts of the results were presented at the annual meeting of the American Society of Nephrology, 2014.
All authors have read the journal’s Authorship Agreement.
CONFLICT OF INTEREST STATEMENT
The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of
Veterans Affairs or the United States Government.
All named authors have reviewed and approved the manuscript. All authors have read the journal’s policy on conflicts of interest.
None of the authors have any conflict of interest to declare regarding the contents of this paper.

Sharma et al.

Page 2

Author Manuscript

monomeric CLCF1 increases Palb, the heterodimer CLCF1-CRLF1 may protect the glomerular
filtration barrier. We speculate that albuminuria in FSGS is related to qualitative or quantitative
changes in the CLCF1-CRLF1 complex and, that JAK2 or STAT3 inhibitors may be novel
therapeutic agents to treat FSGS.

Keywords
Focal segmental glomerulosclerosis; Glomerular filtration barrier; Cardiotrophin-like cytokine 1
Factor; Cytokine Receptor-Like Factor-1; JAK/STAT signaling pathway

INTRODUCTION
Author Manuscript

Focal segmental glomerulosclerosis (FSGS) describes a characteristic histological pattern of
focal and segmental scarring of the glomerulus in renal biopsy. FSGS is associated with
nephrotic syndrome in patients with a variety of etiologies including familial, viral agents,
drug abuse or as part of systemic disease. Current treatment strategies include
immunosuppression, modulation of renal hemodynamics and suppression of fibrosis.
However, current empirical pharmacological interventions are only partially successful.
Idiopathic FSGS remains a difficult medical problem with unknown etiology and only
empirical treatment strategies and, recurs in at least a third of transplant recipients1,2.

Author Manuscript

Recurrence of proteinuria after renal transplantation and remission after repeated plasma
exchange strongly suggest a role of plasma factor(s) but the identity of the causative plasma
factor(s) remains to be confirmed3. Several candidate permeability factors have been
proposed during the last forty years. These include a vascular permeability factor- a T-cell
derived protein4, hemopexin- a plasma protein with protease activity5,6, angiopoietin-like4,
an adipokine7 and soluble urokinase-type plasminogen activator receptor (suPAR)- an
inflammation related molecule8,9. Urokinase (uPA) binds to uPAR and activates
plasminogen to plasmin. Increased levels of suPAR have been interpreted as an indication of
its role as the causative circulating factor in FSGS. Ongoing efforts in this direction are
summarized and evaluated in recent reviews10–12.

Author Manuscript

We have pursued the hypothesis that one or more plasma components cause the initial
damage to podocytes resulting in glomerular dysfunction. We have developed and
extensively used an in vitro assay to study the effect of FSGS serum, plasma or plasma
fractions on isolated rat glomeruli. Using this assay, we have established that recurrent
FSGS plasma, serum or specific plasma fractions increase albumin permeability (Palb) of
isolated glomeruli and, that increased Palb precedes proteinuria after injecting FSGS plasma
fraction in rats13–14. Proteomic analysis of the active fraction using LC-MS/MS led us to
identify cardiotrophin-like cytokine factor 1 (CLCF1)15.
Cardiotrophin-like cytokine factor 1 (CLCF1), a member of the IL-6 family of cytokines, is
also known as novel neurotrophin1 (NNT1) and B cell stimulating factor (BSF3)16–17.
CLCF1 is believed to be secreted and present in circulation as a heterodimeric composite
cytokine with either of two proteins, namely cytokine receptor-like factor-1 (CRLF1) or
soluble receptor alpha for ciliary neurotrophic factor (sCNTF Rα). Co-expression of CLCF1
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with CRLF1 or sCNTF-Rα is considered a requisite for the efficient secretion of CLCF1 and
formation of composite cytokines CLCF1-CRLF1 (CLC-CLF) and CLCF1-sCNTFRα,
respectively18–19.

Author Manuscript

The role of CLCF1 in the regulation of podocyte structure and function is not known.
Studies using cultured neurons show that CLCF1-CRLF1 heterodimer interacts with cells
that express the tripartite receptor complex composed of CNTFRα, gp130 and leukemia
inhibitory factor-β (LIFRβ) and primarily activates the Janus Tyrosine Kinases/ signaling
transducers and activators (JAK/STAT) signaling pathway18. The heterodimer supports the
survival of embryonic motor and sympathetic neurons and induces differentiation of fetal
neuroepithelial cells to astrocytes18,20. Studies using B cells demonstrated the role of
CLCF1 as an effector of JAK/STAT signaling16,18 and its regulatory function in the immune
system through stimulation of B cell proliferation and immunoglobulin production21. Also,
CLCF1-CRLF1 complex is required for fetal kidney development22,23. Thus, CLCF1 may
affect the glomerular filtration barrier through direct interaction with glomerular cells or
through indirect mechanisms. However, the effects of CLCF1-CRLF1 heterodimer complex
or CLCF1 monomer on glomerular barrier function are not known.

Author Manuscript

Since CLCF1 is believed to circulate as a heterodimer, its monomeric and heterodimeric
forms may cause similar or distinct effects on key elements of the JAK/STAT pathway and
modulate glomerular filtration barrier function. Presently, we planned to compare the
glomerular effect of monomeric recombinant CLCF1 with that of the recombinant
heterodimer CLCF1-CRLF1. Increasing evidence highlights the role of JAK/STAT
signaling pathway in glomerular disease24 which makes JAK and/or STAT as potential
targets for treating glomerular disease. In some experiments we compared the effect of
CLCF1 with that of sera from FSGS patients on glomerular albumin permeability in vitro
using anti-CLCF1 antibody or inhibitors of JAK2 and STAT3. Results show that while
monomeric CLCF1 or FSGS serum increased Palb, the heterodimer CLCF1CRLF1attenuated this effect. We also found that commercially available JAK2 or STAT3
inhibitors blocked the effect of CLCF1 or FSGS serum on Palb. Opposite effects of
heterodimer CLCF1-CRLF1 and CLCF1 are in contrast to the reported similarities in their
effects on neuronal cells and suggest cell-type specificity. These results provide an exciting
opportunity to study the role of CLCF1 and related molecules in the etiology of recurrent
FSGS and to explore the potential application of JAK2 and STAT3 inhibitors for treating
FSGS and other glomerular diseases.

METHODS AND MATERIALS
Author Manuscript

Animals
Adult male Sprague-Dawley rats (7–8 weeks old) were obtained from Harlan (Madison, WI)
and maintained at the Animal Resource Facility (ARF), KC VA Medical Center, Kansas
City, MO, under 12/12 hour light/dark cycle with unrestricted access to food and water. The
ARF is approved by the Association for Assessment and Accreditation of Laboratory
Animal Care (AAALAC). Institutional Animal Care and Use Committee (IACUC), Safety
Subcommittee and the Research and Development (R&D) Committee at the KC VA
Medical Center, Kansas City, MO approved the protocol prior to start of these studies. The
Transl Res. Author manuscript; available in PMC 2016 October 01.
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work presented in this manuscript conforms to the relevant ethical guidelines for human and
animal research.
Human serum
Protocol was approved by the Institutional Review Board (IRB). Serum samples were from
de-identified recurrent FSGS patients whose serum specimens caused an increase in Palb
value (≥0.6). Twenty microliter aliquots of each serum sample were used.
Reagents and solutions

Author Manuscript

Recombinant human CLCF1 (rhCLCF1) and CLCF1-CRLF1 (rhCLCF1-CRLF1) and
monoclonal anti-CLCF1 antibody were obtained from R&D Systems, Minneapolis, MN.
Buffers and media were prepared using chemicals obtained from Sigma-Aldrich (St Louis,
MO). Working solutions were prepared in a medium containing 5% BSA. JAK2 inhibitor
BMS-911543 was obtained from Chemietek, Indianapolis, IN. STAT3 inhibitor Stattic was
obtained from Selleck Chemicals, Boston, MA. Stock solutions were prepared and stored
following supplier’s/manufacturer’s guidelines.
Glomerular albumin permeability (Palb) assay

Author Manuscript

Glomeruli from Sprague Dawley rats were used to study changes in glomerular filtration
barrier characteristics using an in vitro assay established in our laboratory13,25. Briefly, rat
glomeruli were isolated as previously described and suspended in a physiological buffer
solution (pH 7.4) containing bovine serum albumin (BSA) 5 gm/dL (isolation/incubation
buffer). Aliquots of isolated glomeruli were treated with control or test agents in the medium
containing 5% BSA for 15 minutes at 37°C in 1 mL total volume. Glomeruli were observed
using video microscopy. A second image of each glomerulus was obtained after changing
BSA concentration in the bath medium to 1%. Change of the medium produces an oncotic
gradient across the glomerular capillary wall (5% BSA in the lumen vs. 1% BSA in the
bathing medium) that causes a net fluid influx and an increase in glomerular volume.

Author Manuscript

Glomerular diameter was measured at four coordinates 45° apart. The average of 4
diameters was used to calculate the volume of each glomerulus in 5% BSA and 1% BSA,
respectively. The change in volume (ΔV) of each glomerulus in response to the oncotic
gradient was calculated as: ΔV = (Vfinal-Vinitial)/ Vinitial X 100 % .The increase in
glomerular volume (ΔV) is directly related to the oncotic gradient (DP) applied across the
capillary wall. We apply this principle to calculate reflection coefficient (σalb) using the ratio
of ΔV of experimental to ΔV of control glomeruli in response to identical oncotic gradient:
σalb= ΔVexperimental/ΔVcontrol Convectional albumin permeability (Palb) is defined as (1-σalb)
and describes the movement of albumin consequent to water flow. When σalb is zero,
albumin moves at the same rate as water and Palb is 1.0. When σalb is 1.0, albumin cannot
cross the membrane with water and Palb is zero.
Western Blotting
Glomeruli were incubated with CLCF1 (0.05–100 ng/mL) with or without CLCF1-CRLF1
as indicated. Glomeruli were homogenized in a lysis buffer containing Sigma Fast Protease
Inhibitor (S8820, 119K8203 Sigma-Aldrich) and phosphatase inhibitors (P5726 and P0044,
Transl Res. Author manuscript; available in PMC 2016 October 01.
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Sigma-Aldrich) using a sonicator and the lysate was centrifuged at 12,000g for 5 minutes.
Total protein was determined using a kit based on Lowry’s assay (BioRad, Hercules, CA).
The supernatant was frozen at −70°C. Phospho-STAT3 (pSTAT3, Tyr 705) was determined
by Western blotting followed by imaging and density analysis. Beta-actin (β-actin) was used
as the loading control.

Author Manuscript

Total glomerular protein lysate was electrophoresed by SDS-PAGE using TGX gels
(BioRad) followed by electro-transfer to PVDF membrane and detection using specific
primary antibodies. Rabbit anti-pSTAT3 (Tyr705 D3A7, Cell Signaling catalog# 9131,
1:1000 dilution) was used in 5% BSA TBST. Mouse anti-β-Actin (Sigma catalog# A5441,
1:10000) was used in 5% dry milk in TBST. HRP-conjugated secondary antibodies for
pSTAT3 (Tyr 705) and β-actin were goat anti-rabbit HRP conjugate (BioRad, catalog#
1705046, 1:10,000 dilution) and goat anti-mouse HRP conjugate (BioRad, catalog# 170–
5047, 1:10,000), respectively. ECL Prime Western Blotting Detection reagent (GE
Healthsciences, Piscataway, NJ) was used for chemiluminescence reaction and images were
obtained using Kodak Gel Logic 2200 imaging system (Carestream Health Inc., New Haven
CT). Image intensity data were normalized by loading control β-actin. Normalized intensity
ratios were used to present data as bar graphs shown. The effect of CLCF1 on STAT3 (Tyr
705) phosphorylation and its attenuation by CLCF1-CRLF1 at various concentrations were
determined.
Statistical analyses
Descriptive statistics such as means and proportions were used. Mean values were compared
using Student’s t-test. P<0.05 was accepted as significant.

Author Manuscript

RESULTS
CLCF1 increases Palb in a dose-dependent manner and anti-CLCF1 antibody blocks the
increase in Palb
Recombinant human CLCF1 (rhCLCF1, CLCF1, 0.05–100 ng/mL) increased glomerular
Palb in a dose-dependent manner within 15 minutes (Figure 1A). Significant increase in Palb
was evident at CLCF1 concentrations as low as 0.05 ng/mL. A maximal increase was
observed at 5–10 ng/mL (P<0.001) and CLCF1 was used at these concentrations in other
experiments to study its effect on glomerular filtration barrier. These results show that,
CLCF1 alters glomerular filtration barrier characteristics at sub-nanomolar concentrations.

Author Manuscript

Anti-CLCF1 monoclonal antibody blocked the increase in Palb caused by CLCF1 (Figure
1B). Glomeruli were incubated with CLCF1 (5ng/mL) or with a mixture of CLCF1 and antiCLCF1 antibody (0.05–50mg/mL) for 15 min. Control group included 5 µg/mL human IgG.
CLCF1 caused a significant increase in Palb (P<0.001 vs. Control) that was progressively
blunted by increasing amounts of the antibody with a maximum effect at 50 µg antibody
(P<0.005 vs. CLCF1 alone).
Anti-CLCF1 monoclonal antibody also blocked the increase in Palb caused by sera from five
patients with recurrent FSGS (Figure 1C). Incubation with each FSGS serum caused
increase in Palb with an average of 0.69 (P<0.001 vs. control). Pre-mixing the serum with
Transl Res. Author manuscript; available in PMC 2016 October 01.
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anti-CLCF1 antibody blocked the effect of FSGS serum and the final average Palb was 0.22
(P<0.005 vs. FSGS serum alone, n=5). Thus, the effect of anti-CLCF1 antibody on different
FSGS serum specimens varied between samples and resulted in 32–94% attenuation of Palb.
CLCF1-CRLF1 complex does not affect Palb and blocks the effect of CLCF1
Incubation with the heterodimer CLCF1-CRLF1 (0.1–10ng/mL) did not increase glomerular
Palb (Fig 2A). This finding contrasts the effect of CLCF1 monomer that caused a significant
increase in Palb (Figure 1A). These findings led to the following experiments to determine
the effect of CLCF1 on Palb in presence of the heterodimer CLCF1-CRLF1.

Author Manuscript

Figure 2B shows the blocking effect of CLCF1-CRLF1 on the CLCF1-induced increase in
Palb. Glomeruli were incubated with CLF1 or CLCF1-CRLF1 for 15 minutes as before.
Additionally, glomeruli were incubated with CLCF1-CRLF1 heterodimer (5–20 ng/mL) for
15 min followed by addition of CLCF1 (5 ng/mL) and further incubation for 15 minutes.
While CLCF1 alone caused a significant increase in Palb, the CLCF1-CRLF1 heterodimer
did not affect Palb confirming results of earlier experiments (Figure 2A). Pre-incubation with
5 ng/mL CLCF1-CRLF1 attenuated the effect of CLCF1 on Palb (P<0.02 vs. CLCF1 alone).
Higher concentrations of CLCF1-CRLF1 complex (10 or 20ng/mL) caused greater
attenuation of Palb (P<0.005 vs. control).

Author Manuscript

These results show that pre-treatment with the heterodimer CLCF1-CRLF1 prevents the
effect of CLCF1 and protects the glomerular filtration barrier from CLCF1 induced increase
in Palb. These findings are in contrast to previously reported effect of CLCF1 and the
heterodimer CLCF1-CRLF1 on neuronal cells. CLCF1-CRLF1 complex was found to have
greater neuropoietic/neurotrophic effect. We conclude that the receptor complex and/or
signaling events initiated in glomerular podocytes are unique and differ from those in
neurons or B cells.
Pre-incubation of glomeruli with CLCF1-CRLF1 blocks the effect of FSGS serum on Palb
We sought to corroborate the blocking effect of CLCF1-CRLF1 on CLCF1-induced increase
in Palb using FSGS serum. Figure 3A shows that CLCF1-CRLF1 blocked the increase in
Palb caused by FSGS serum. Isolated glomeruli were pre-incubated with CLCF1-CRLF1
heterodimer (5–50 ng/mL) for 15 minutes followed by addition of FSGS serum (20 mL/mL)
and further incubation for 15 minutes. FSGS serum caused a significant increase in Palb (#,
P<0.001 vs. control) and CLCF1-CRLF1 attenuated the effect of FSGS serum. CLCF1CRLF1 complex at 10 (P<0.02 vs. FSGS alone), 20 ng/mL (P<0.005 vs. FSGS alone) and
50 ng/mL (P<0.005 vs. FSGS alone) blocked the effect of FSGS serum.

Author Manuscript

We planned to further confirm that the active component in FSGS serum and the
heterodimer CLCF1-CRLF1 interact with the same site on the glomerulus. Figure 3B shows
results of experiments using an alternate strategy to determine the effect of CLCF1-CRLF1
complex on FSGS serum-induced increase in Palb. For this purpose, we changed the order of
adding FSGS serum and the heterodimer to glomerular suspension. Isolated glomeruli were
pre-incubated with FSGS serum for 15 minutes followed by addition of CLCF1-CRLF1 (5–
50 ng) and further incubation for 15 minutes. FSGS serum with or without CLCF1-CRLF1
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Sharma et al.

Page 7

Author Manuscript

increased Palb significantly (*, P<0.001 vs. control). These data show that pre-incubation
with FSGS serum prevented the interaction between the heterodimer and the glomerular
binding site. Thus, CLCF1-CRLF1 failed to prevent the effect of FSGS serum factor shown
in Figure 3A. Results summarized in Figures 3A and 3B suggest that FSGS serum factor and
the heterodimer CLCF1-CRLF1 appear to bind to the same glomerular site(s) and each
prevents the binding of the other. These results also imply that CLCF1 and FSGS serum
component(s) interact with the same receptor proteins that are blocked by the heterodimer.
Effect of the heterodimer CLCF1-CRLF1 is receptor specific

Author Manuscript

i. CLCF1-CRLF1 heterodimer does not block the effect of TNFa or IL6—In the
next set of experiments, we selected two cytokines, namely TNFα and IL6 that individually
can increase glomerular Palb. TNFα and IL6 are ligands for specific receptors that activate
distinct signaling pathways and each can increase Palb. TNFα acts through its unique
receptors, and IL6 binds to IL6Rα-gp130 complex. CLCF1 is a member of the IL6 family of
cytokines and shares gp130 as a receptor component with other members of the IL6
family26.
Figure 4A shows that pre-incubation of glomeruli with CLCF1-CRLF1 (5–20 ng/mL) for 15
minutes followed by addition of TNFα (10 ng/mL) or IL6 (1 ng/mL) did not block the
increase in Palb caused by either of these cytokines. These results are in contrast to the effect
of CLCF1-CRLF1 on CLCF1-induced increase in Palb where the heterodimer blocked the
effect of CLCF1.

Author Manuscript

These results suggest that the monomeric CLCF1 and the heterodimer CLCF1-CRLF1
compete for the receptor complex CNTFRα-gp130-LIFRβ, and that TNFα and IL6 do not
mediate their effects on Palb through this receptor complex. The antagonistic effect of
CLCF1-CRLF1 heterodimer against CLCF1 is therefore receptor specific. Thus, we
confirmed the specificity of the blocking effect of CRLF1-CLCF1 complex using two other
cytokines that do not interact with the tripartite receptor complex for CLCF1.

Author Manuscript

ii. CLCF1-CRLF1 heterodimer blocks the CLCF1-induced upregulation of
STAT3 phosphorylation—FigureS 4B and 4C summarize the results that demonstrate a
specific effect of the heterodimer CLCF1-CRLF1 on CLCF1-induced activation of the JAK/
STAT signaling pathway. Isolated rat glomeruli were pre-incubated with CLCF1 (10 ng/mL,
MW ~ 25 kDa) for 15 minutes or with CLCF1-CRLF1 (10–40 ng/mL, MW. ~72 kDa) for 15
minutes followed by addition of CLCF1 (10 ng/mL) and incubation for 15 minutes at 37°C.
Thus, the ratio of CLCF1 to the heterodimer CLCF1-CRLF1 ranged from 1:1 to 1:4 (ng:ng).
These amounts provided an approximate molar ratio of 1:0.3–1:1.25 (CLCF1 : CLCF1CRLF1).
Results of SDS-PAGE followed by Western blotting for pSTAT3 (Tyr705) are presented in
Figure 4B. Blots were analyzed by semi-quantitative image analysis and experimental/
control ratios of normalized intensities for pSTAT3 (Tyr705) are presented in Figure 4C.
These results show that pre-treating glomeruli with CLCF1-CRLF1 complex attenuated the
CLCF1-induced increase in STAT3 phosphorylation (*, P<0.001 vs. CLCF1 alone).
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Earlier in this series of experiments, data presented in Figures 2 and 3 showed that the
heterodimer CLCF1-CRLF1 blocked the effect of CLCF1 on Palb in a manner that suggested
their action through a shared binding site on the tripartitereceptor complex. Since CLCF1
activates the JAK/STAT signaling pathway, results in Figures 4B and 4C lead us to surmise
that the heterodimer CLCF1-CRLF1 attenuates the CLCF1-induced increase in Palb through
down regulation of STAT3 phosphorylation.
JAK2 inhibitor blocks the effect of CLCF1 and FSGS serum on Palb

Author Manuscript

CLCF1 binding to the tripartite receptor activates JAK/STAT signaling17,18. The binding of
CLCF1 to the receptor complex results in phosphorylation of JAK2 at specific sites18. To
further determine the role of JAK/STAT pathway in CLCF1-induced increase in Palb we
used BMS-911543 (BMS), a commercially available JAK2 specific small molecular weight
inhibitor (IC50 ≤ 2 nM)27. Isolated rat glomeruli were pre-incubated with JAK2 inhibitor
BMS-911543 (BMS, 1–10 nM) for 15 minutes followed by addition of CLCF1 (10 ng/mL)
or FSGS serum (20 µL/mL) for 15 minutes.
Figure 5 shows that BMS (1–10 nM) alone did not affect Palb and CLCF1 or FSGS serum
caused increase in Palb. Pre-treatment of glomeruli with BMS significantly blocked the
effect of CLCF1 (P<0.001 vs. CLCF1 alone) or FSGS (P<0.001 vs. FSGS serum alone).
These results show that CLCF1 activates JAK2 and the resulting increase in Palb is
significantly blocked by a JAK2-specific inhibitor. Thus, CLCF1-induced phosphorylation
of JAK2 confirms receptor-ligand interaction that can be blocked by a specific inhibitor at
very low concentrations.

Author Manuscript

Table 1 summarizes the effect of JAK2 inhibitor BMS911543 on sera from five patients
with recurrent FSGS. Earlier experiments showed that CLCF1-induced increase in Palb is
comparable to that caused by FSGS sera (Figures 1A, 1C). Pre-incubation with JAK2
inhibitor significantly but partially blocked the effect of FSGS sera on Palb. Average
increase in Palb dropped from 0.78 (range 0.69 to 0.82) to 0.44 (range 0.42 to 0.50)
following pre-treatment of glomeruli with JAK2 inhibitor. Thus, pretreatment with JAK2
inhibitor resulted in a 43% (28–49%) attenuation of the effect of FSGS serum on Palb.
STAT3 inhibitor blocks the effect of CLCF1 and FSGS serum on Palb

Author Manuscript

Low molecular weight compound Stattic is a specific inhibitor of STAT3 activation28. We
tested its effect on CLCF1 and FSGS serum-induced increase in Palb. Isolated rat glomeruli
were pre-incubated with Stattic (0.05–1 µM) for 15 minutes followed by addition of CLCF1
(10 ng/mL). In separate experiments, glomeruli were pre-incubated with Stattic (0.1 or 1
µM) for 15 minutes followed by FSGS serum (20 µL/mL) for 15 minutes. Pre-incubation
with Stattic (1 µM) blocked the effect of FSGS serum on Palb (P<0.001).
Table 1 also summarizes the effect of STAT3 inhibitor Stattic on FSGS serum samples from
five patients with recurrent FSGS. Pre-incubation with Stattic inhibitor significantly
(P<0.001) blocked the effect of FSGS sera on Palb. Average increase in Palb dropped from
0.78 (range 0.69 to 0.82) to 0.38 (range 0.32 to 0.47) after pre-treatment of glomeruli with
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Stattic. Thus, pretreatment with STAT3 inhibitor resulted in a 51% (43–57%) attenuation of
the effect of FSGS serum on Palb.

DISCUSSION

Author Manuscript

Three main findings emerged from these studies. First, we discovered that monomeric
recombinant CLCF1 increased Palb comparable to FSGS serum. A monoclonal anti-CLCF1
antibody attenuated the effect of CLCF1 or FSGS serum on Palb. Second, the heterodimer
CLCF1-CRLF1 blocked the effect of CLCF1 or FSGS serum on Palb but showed no effect
on Palb by itself and did not attenuate the effect of TNFα or IL6. Finally, commercially
available inhibitors of JAK2 or STAT3 blocked the effect of CLCF1 or FSGS serum on Palb.
We believe these novel data provide valuable information on the role of circulating CLCF1
in idiopathic FSGS and an opportunity to investigate the potential repurposing of available
JAK inhibitors to treat the effect of the circulating plasma factor on glomerular function.
A circulating factor was postulated about forty years ago and putative candidates have
included cytokines released from activated T cells4,29–32. Ongoing efforts in different
laboratories are focused on circulating molecules with diverse ontologic roles that appear to
converge on glomerular pathophysiology. Current candidate molecules include vascular
permeability factor4, hemopexin5,6, angiopoietin-like47 and suPAR8,9 Several studies have
addressed the clinical and molecular aspects of suPAR as a circulating factor in FSGS.
Several issues including its significance as a causative factor or specific indicator of FSGS
and, its role as a mediator of glomerular/renal changes are subjects of ongoing research and
discussion33,34. Soluble uPAR is associated with the uPA/uPAR plasminogen activation
mechanism and its levels positively correlate with several inflammatory conditions
including, cancer, infection and systemic disease35.

Author Manuscript
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Since the role of CLCF1 in glomerular pathophysiology is not known, we planned to first
determine its effect on glomerular barrier function using an in vitro assay developed in our
laboratory. The glomerular permeability (Palb) assay is a functional assay based on
glomerular response an experimental oncotic gradient in the presence/absence of potential
mediator(s) of glomerular injury or protection. The assay detects diminished reflection
coefficient that corresponds to increased convectional permeability by measuring the effect
of FSGS plasma (or other reagent) on glomerular filtration in response to an experimental
oncotic gradient. This assay serves to demonstrate the earliest changes in the glomerular
filtration barrier that lead to increased filtration of albumin and eventually to proteinuria.
Currently, it is the only assay that detects the changes in glomerular function that result from
a circulating substance in FSGS serum/plasma. This assay has been used for testing of
>2200 serum samples of pre- and post-transplant patients from across the world.
Specifically, the assay detects robust Palb increasing effect of recurrent FSGS and the pretransplant sera. Results have consistently shown that a Palb value of ≥0.5 is strongly
associated with recurrence of FSGS36. Plasmapheresis decreases permeability activity in a
manner consistent with the removal of a molecule that is present primarily in the plasma
space. Activity gradually returns to prior levels several weeks after multiple plasma
exchange treatments. We have shown that this assay discriminates between the effect of sera
from recurrent FSGS and other glomerular disease including post-transplant membranous
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glomerular nephropathy and minimal change disease36. In other studies, we have shown that
glomerular albumin permeability increases before proteinuria occurs. These include
experiments performed after injecting FSGS plasma preparation14, rat models of
hypertension37 and radiation nephropathy38. In each of these models, glomerular
permeability increased prior to increase in Up/Uc ratio. We have used this assay extensively
to determine the effect of cytokines, antibodies, metabolites and free radicals. We have also
used this technique to detect the permeability factor in FSGS plasma and to follow the
permeability activity in enriched plasma fractions. Recent reviews summarize the
applications of this assay in our studies on recurrent FSGS, identification of agents that are
protective or injurious to the glomerular protein permeability barrier3,39.
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A comparable increase in Palb by CLCF1 and sera from patients with recurrent FSGS
(Figure-1A, 1C), and a significant blockade of increase in Palb by anti-CLCF1 antibody
(Figure 1B, 1C) suggested a potential role for CLCF1 in the early events leading to loss of
glomerular barrier function observed in recurrent FSGS. A distinct role of monomeric
CLCF1 in glomerular pathophysiology is not clear since previous studies using neurons
have highlighted its role as a heterodimer with CRLF140. First, CLCF1 shows optimum
neuropoietic and neurotrophic effects as a heterodimer with CRLF118,41. Second, CLCF1 is
essential for lumbar and facial motoneuron differentiation42,43 and, mutations in CLCF1
result in cold-induced sweating syndrome (CISS) 45,46. Mutations in CRLF1 gene are also
associated with CISS and Crisponi syndrome46. In one recent case study CISS presented
with complications in the urinary system including a smaller than normal right kidney and
persistent mild hypernatremia that were interpreted to indicate a role of CLCF1 in renal
development47. Additionally, CRLF1 is required for normal kidney development during
embryogenesis22,23. CRLF1 and CLCF1 appear to function as a heterodimer in neuronal
differentiation and renal development but the role of monomeric CLCF1 in glomerular
function is not known.
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In contrast to its effect on neurons, the CLCF1-CRLF1 composite cytokine did not augment
or parallel the effect of CLCF1 on Palb. Instead, it antagonized the effect of both monomeric
CLCF1 (Figure 2B) and FSGS serum (Figure 3A). In each case, inhibition was dosedependent and apparently competitive. CLCF1 and CLCF1-CRLF1 appear to interact with
the same molecular component of the receptor complex since pre-treatment of glomeruli
with FSGS serum prevented the blocking effect of the heterodimer (Figure 3B). We
addressed the specificity of the effect of CLCF1-CRLF1 on CLCF1-mediated increase in
Palb by demonstrating that the heterodimer does not block the increase in Palb caused by
unrelated cytokines TNFα or IL6 (Figure 4A). The antagonistic effect of the CLCF1-CRLF1
complex on the CLCF1-induced increase in Palb is a novel and significant finding that will
serve to further explore the diversity of gp130-associated receptor complexes and signaling
elements. These observations have led us to conclude that the effect of CLCF1-CRLF1
complex on the glomerular filtration barrier differs from its effect on neurons where it
causes similar and stronger response compared to monomeric CLCF1. These observations
prompted the use of CLCF1-CRLF1 complex as a natural antagonist of CLCF1 in studies
involving JAK/STAT signaling in glomeruli. Further, CLCF1-CRLF1 will be a valuable tool
for future studies on the JAK/STAT pathway in podocytes.
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Receptor activation by CLCF1 causes conformational changes in the intracellular regions of
receptor proteins and phosphorylation of JAK218. JAK isoforms serve as sentinels of the
JAK/STAT signaling pathway in mediating the cellular effects of several ligands through
phosphorylation of STATs48. Our preliminary work showed that JAK2 and STAT3 are
dominant isoforms in glomeruli and podocytes (data not presented here). JAK2 may be a
potential target for regulating the CLCF1-induced over-activation of JAK/STAT signaling
pathway. BMS-911543, used in the present experiments is a potent and selective small
molecule inhibitor of the JAK2 (IC50 ≤ 2nM)27. We found that BMS911543 blocks the
effect of both CLCF1 and FSGS serum. To our knowledge, this is the first report
demonstrating the effect of BMS-911543 on glomerular barrier function but other JAK2
inhibitors have been tested in animal models. For example, in the mouse model of
adriamycin-induced nephrotic syndrome, post-injury administration of JAK2 inhibitor AG
490 for 6 weeks decreased proteinuria, serum creatinine, glomerulosclerosis,
tubulointerstitial lesions and renal alpha-smooth muscle actin (α-SMA) expression. AG490
also inhibited the expression of monocyte chemoattractant protein (MCP-1) mRNA and
reduced interstitial infiltration of macrophages and T cells49. BMS-911543 and several small
molecules are at advanced stages of clinical trials (Tofacitinib, Pfizer; INCB28050, Lilly/
Incyte). Tofacitinib (Xeljanz, Pfizer) and Ruxolinitib/Jakafi, (Novartis/Incyte) have been
approved by the US FDA. Potential off-label applications of these compounds are already
under consideration50.
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JAK2-mediated phosphorylation of STAT3 leads to transcriptional regulation of a number
of genes. The diverse effects of STAT3 appear to be determined by post-translational
modifications, dimerization and by whether or not it translocates to the nucleus. Briefly,
activation of STAT3 involves phosphorylation at tyrosine 705 (Tyr705/Y705), translocation
to the nucleus and binding to interferon-gamma-activated sequences for transcription
initiation51–54. In addition, phosphorylation of serine (S) residues in STATs (S727 in
STAT3) may affect STAT translocation positively or negatively depending upon the cell
type and activation status of STAT, nature of the gene promoter and extracellular factors55.
Phosphorylation of serine without tyrosine phosphorylation51 and phosphorylation of
mitochondrial STAT356–58 are other modes of STAT3 activation. Additional posttranslational modifications of STAT3 may influence its function. For example, acetylation
of STAT3 in response to certain stimuli51 is responsible for its role in oxidative changes in
diabetic nephropathy59 and in the down regulation of autophagy60,61. Recent data show that
native unphosphorylated STAT3 can also move between the nucleus and cytoplasm
suggesting that phosphorylation may not be a critical requirement, at least in certain
cells62,63. Thus, STAT3 can influence both nuclear and cytoplasmic processes with or
without phosphorylation or acetylation64,65. We limited the present studies to CLCF1induced phosphorylation of STAT3 at tyrosine 705 but changes at other sites of STAT3
molecule and their role in the cellular effects of CLCF1 need to be studied.
Over-activation of STAT3 in podocytes is associated with glomerular disease and its downregulation attenuates the glomerulonephritis induced by nephrotoxic serum66, HIVAN67 and
diabetic nephropathy59. The diverse nature and wide range of its effects through multiple
mechanisms has made STAT3 a highly sought after target for potential inhibitors derived
from peptides, non-peptide small molecules, oligonucleotides, natural and synthetic
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molecules68,69. Stattic, a synthetic small molecule, specifically inhibits (IC50= 5.1µM)
activation, dimerization, and nuclear translocation of STAT3, and increases the apoptotic
rate of STAT3-dependent breast cancer cell18. We found that Stattic concentrations below
its IC50 significantly protected against increase in Palb (Figure 6). Thus, concentrations of
STAT3 inhibitor(s) required may depend on the cell type and reflect constitutive
overexpression or induced over-activation of STAT3. In addition, our results also show that
CLCF1-induced upregulation of STAT3 phosphorylation was attenuated by the heterodimer
CLCF1-CRLF1 (Figure 4B–C). Thus, loss of equilibrium between the levels of circulating
CLCF1 and the heterodimer CLCF1-CRLF1 may result in over-activation of STAT3
phosphorylation.
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In summary, CLCF1, a member of the IL6 family of cytokines, or FSGS plasma increases
Palb and activates the JAK2/STAT3 pathway in glomeruli. In contrast, the heterodimer
CLCF1-CRLF1 blocks these effects of CLCF as well as the comparable effect of FSGS
serum on Palb. Opposing effects of CLCF1 and CLCF1-CRLF1 on glomerular filtration
barrier are in contrast to their parallel neurotrophic/neuropoietic and immune-modulatory
effects. We interpret the increase in Palb by CLCF1 or FSGS sera and an upregulation of
JAK/STAT activation as evidence in support of a central role of the JAK/STAT pathway in
glomerular response to FSGS serum/plasma. The finding that inhibitors of JAK2 or STAT3
activation prevent FSGS-induced increase in Palb suggests a potential value of these
molecules in treating chronic glomerular disease.
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CLCF1

Cardiotrophin-like cytokine Factor-1

CNTF

Ciliary Neurotrophic Factor

CNTFRα

Ciliary Neurotrophic Factor Receptor alpha

sCNTFRα

Soluble Cilliary Neurotrophic Factor Receptor alpha

CRLF1

Cytokine Receptor-Like Factor-1

FSGS

Focal Segmental Glomerulosclerosis

gp130

Glycoprotein130

IL6

Interleukin −6

JAK

Janus Kinase
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LIFRβ

Leukemia Inhibitory Factor Receptor-β

STAT

Signal Transducer and Activator of Transcription

TNFβ

Tumor Necrosis Factor-α
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Brief Commentary
Background: A circulating factor is believed to cause recurrence of idiopathic focal
segmental glomerulosclerosis (FSGS) after renal transplantation. Recently we identified
cardiotrophin-like cytokine 1 (CLCF1) in the plasma from recurrent FSGS patients.
Present studies show that recombinant CLCF1 and FSGS serum induce comparable
increase in glomerular albumin permeability in vitro that can be blocked by JAK2 or
STAT3 inhibitors.
Translational significance: These novel findings suggest a significant role of CLCF1 in
the early glomerular pathophysiology of recurrent FSGS. FDA approved JAK inhibitors
may be useful in regulating the JAK2/STAT3 signaling to treat recurrent FSGS and other
glomerular disease.
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Figure 1.

1A. CLCF1 caused an increase in glomerular albumin permeability (Palb). Isolated rat
glomeruli were incubated with recombinant CLCF1 (0.05–100ng) for 15 minutes at 37°C.
CLCF1 at 0.05ng/mL concentration caused significant increase in Palb (P<0.05 vs. control).
Maximal increase was observed at 5–10 ng/mL (P<0.001). N= 15 glomeruli from 3 rats (5
glomeruli from each rat) in each group.
1B. Anti-CLCF1 antibody blocked the effect of CLCF1 on Palb. Isolated rat glomeruli
were incubated with recombinant CLCF1 (5ng/mL) or with a mixture of CLCF1 and anti-
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CLCF1 monoclonal antibody (0.05–50µg /mL) for 15 minutes at 37°C. Control group
included 5 µg human IgG. CLCF1 caused significant increase in Palb (P<0.001 vs. Control)
that was maximally blocked by antibody at 50 µg /mL concentration (*, P<0.005 vs. CLCF1
alone). N= 15 glomeruli from 3 rats (5 glomeruli from each rat) in each group.
1C. Anti-CLCF1 antibody blocked the effect of sera from patients with recurrent
FSGS. Isolated glomeruli were incubated with FSGS serum samples from five individuals
(20 µL/mL each) or with a mixture of each serum sample and anti-CLCF1 antibody
(50µg/mL) for 15 minutes at 37°C. Control group included 20µL/mL of pooled normal
serum. Each pair of black and grey bars represents one sample. Black bars show that each
FSGS serum sample caused significant increase in Palb (P<0.001 vs. Control). Each grey bar
shows the effect of anti-CLCF antibody on the corresponding FSGS sample. Numeric values
for Palb and percent change are shown under each pair of black and grey bars for each
sample. Average of all five samples with SEM (mean±SEM) shows that anti-CLCF1
antibody significantly blocked the effect of FSGS serum (P<0.005, n=5 specimens). Five
glomeruli from 1 rat were observed to calculate Palb for each sample.
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Figure 2.

2A. Heterodimer CLCF1-CRLF1 complex did not increase Palb. Isolated rat glomeruli
were incubated with recombinant CLCF1-CRLF1 (0.1–10ng/mL) for 15 minutes at 37°C.
CLCF1-CRLF1 did not affect Palb at any of the concentrations used. N=15 glomeruli from 3
rats (5 glomeruli from each rat) in each group.
2B. Heterodimer CLCF1-CRLF1 heterodimer blocked the effect of CLCF1 on Palb.
Isolated rat glomeruli were pre-incubated with CLCF1-CRLF1 (5–20ng/mL) for 15 minutes
followed by addition of CLCF1 (5ng/mL) for 15 minutes at 37°C. CLCF1 alone caused a
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significant increase in Palb (#, P<0.001 vs. control or CLCF1-CRLF1 alone) and pretreatment with CLCF1-CRLF1 blocked the effect of CLCF1 in a dose-dependent manner (*,
P<0.02 vs. CLCF1 alone; **, P<0.005 vs. CLCF1 alone). N=15 glomeruli from 3 rats (5
glomeruli from each rat) in each group.
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Figure 3.

3A. Pre-treatment of glomeruli with CLCF1-CRLF1 heterodimer blocked the effect of
FSGS serum on Palb. Isolated glomeruli were pre-incubated with CLCF1-CRLF1 complex
(5–50ng/mL) for 15 minutes followed by addition of FSGS serum (20µL/mL) and
incubation for 15 minutes at 37°C. FSGS serum alone caused a significant increase in Palb
(#, P<0.001 vs. Control) that was blocked by 10ng/mL (*, P<0.02 vs. FSGS alone), 20ng or
50ng/mL (**, P<0.005 vs. FSGS alone). N= 15 glomeruli from 3 rats (5 glomeruli from
each rat) in each group.
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3B. Pre-treatment with FSGS serum prevented the protective effect of CLCF1-CRLF1
heterodimer on Palb. Isolated glomeruli were pre-incubated with FSGS serum (20µ/mL) for
15 minutes at 37°C followed by addition of CLCF1-CRLF1 (5–50 ng/mL) for 15 minutes at
37°C. FSGS serum with or without CLCF1-CRLF1 increased Palb significantly (*, P<0.001
vs. control). N= 15 glomeruli from 3 rats (5 glomeruli from each rat) in each group.
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Figure 4.

4A. Pre-incubation of glomeruli with CLCF1-CRLF1 heterodimer did not block the
effect of TNFα or IL6. Isolated rat glomeruli were pre-incubated with CLCF1-CRLF1 (5–
20 ng/mL) for 15 minutes followed by addition of TNFa (10ng/mL) or IL6 (1 ng/mL) and
further incubation for 15 minutes at 37°C. TNFα and IL6 each caused a significant increase
in Palb compared to control (*, P<0.001 vs. control). CLCF1-CRLF1 did not block the
increase in Palb caused by TNFα or IL6. N=15 glomeruli from 3 rats (5 glomeruli from each
rat) in each group.
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4B and 4C. CLCF1-CRLF1 heterodimer blocked the CLCF1- induced phosphorylation
of STAT3. Figure 4B shows a representative Western blot image to demonstrate the
upregulation of STAT3 (Tyr705) phosphorylation by CLCF1 and the blocking effect of
CLCF1-CRLF1 heterodimer. Control group represents untreated glomeruli. Glomeruli were
incubated with CLCF1 (10ng/mL) for 15 minutes in one group. In additional groups,
glomeruli were pre-incubated with heterodimer CLCF1-CRLF1 (10–40ng/mL) for 15
minutes followed by addition of CLCF1 (10ng/mL) and incubation for 15 minutes at 37°C.
Thus, the ratio of CLCF1 to the heterodimer CLCF1-CRLF1 ranged from 1:1 to 1:4 (ng:ng)
or a molar ratio of approximately 1:0.3 to 1:1.25. Total protein lysates were resolved by
SDS-PAGE followed by Western blotting using anti-pSTAT3 (Tyr705) as the primary
antibody.
Figure 4C. The bar graph shows results of quantitative analysis of protein band intensities.
Changes in STAT3 phosphorylation (Tyr705) were determined by semi-quantitative image
analysis. Background subtracted intensities were normalized by the loading control β-actin.
Ratios of intensities (Experimental/control) are presented in the bar graph. CLCF1 caused
significant increase in pSTAT3 (Tyr705) (*, P<0.001 control vs. CLCF1 alone). CLCF1induced increase in pSTAT3 (Tyr705) was attenuated by pretreatment with 30 or 40 ng/mL
CLCF1-CRLF1 (*, P<0.001 vs. CLCF1 alone). Mean±SEM of three separate experiments
are shown.
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Figure 5.

JAK2 inhibitor blocked the effect of CLCF1 or FSGS serum on Palb. Isolated rat
glomeruli were pre-incubated with JAK2 inhibitor BMS-911543 (BMS, 1–10nM) for 15
minutes followed by addition of CLCF1 (10ng) or FSGS serum (20µL) for 15 minutes at
37°C. BMS blocked the effect of CLCF1 or FSGS serum at 5 and 10 nM concentrations and
increased Palb. (*, P<0.001 vs. CLCF1 alone; #, P<0.001 vs. FSGS alone; Mean±SEM, N=
15 glomeruli from 3 rats, 5 glomeruli from one rat in each group).
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STAT3 inhibitor blocked the effect of CLCF1 and FSGS serum on Palb. Isolated rat
glomeruli were pre-incubated with STAT3 inhibitor Stattic (0.001–1µM) for 15 minutes
followed by addition of CLCF1 (10ng/mL). In separate experiments, glomeruli were preincubated with Stattic (0.1 or 1µM) for 15 minutes followed by FSGS serum (20µL/mL) for
15 minutes at 37°C. Pre-treatment of glomeruli with Stattic (0.05–1µM) significantly
blocked the effect of CLCF1 (P<0.001 vs.CLCF1 alone). Pre-incubation with Stattic (1µM)
blocked the effect of FSGS serum on Palb. (#, P<0.001 vs. FSGS alone). N=15 glomeruli
from 3 rats (5 glomeruli from each rat) in each group.
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1

2

3

Palb
FSGS
seruma
Untreated

Palb
FSGS Serum +
JAK2 Inhibitora,b
(percent decrease, 1–2)

Palb
FSGS Serum +
STAT3 Inhibitora,c
(percent decrease, 1–3)

Recurr (M)

0.75

0.44 (41)

0.32 (57)

Recurr (M)

0.82

0.42 (49)

0.35 (57)

Recurr (M)

0.77

0.42 (46)

0.36 (53)

2nd Recurr (M)

0.69

0.50 (28)

0.41 (43)

Recurr (M)

0.88

0.42 (52)

0.47 (47)

Mean

0.78

0.44 (43)

0.38 (51)

SD

0.06

0.031

0.0526

SEM

0.028

0.0138

0.0235

<0.001

<0.001

P value 1 vs. 2 or 3
a

Each value represents the mean of 5 glomeruli observed.

b

Glomeruli were incubated with JAK2 inhibitor BMS 911543 (5µM) for 15 minutes followed by addition of FSGS serum and incubation for 15
minutes at 37°C.
c

Glomeruli were incubated with STAT3 inhibitor Stattic (1µM) for 15 minutes followed by addition of FSGS serum and incubation for 15 minutes
at 37°C.
Abbreviations: M- Male; Recurr- Recurrence
Control Palb 0.003±0.041
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